3-fluoro-4-(3-chloro-5-pyridyloxy)aniline | 315226-55-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-fluoro-4-(3-chloro-5-pyridyloxy)aniline
• 英文别名: 4-(5-chloropyridin-3-yl)oxy-3-fluoroaniline
• CAS: 315226-55-2
• 化学式: C₁₁H₈ClFN₂O
• 分子量: 238.649
• InChiKey: GPSKAMCTSOKWIE-UHFFFAOYSA-N

物化性质

• 沸点：
  345.4±42.0 °C(Predicted)
• 密度：
  1.390±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-fluoro-4-(3-chloro-5-pyridyloxy)aniline 、 2,4-二氯苯磺酰氯 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 生成 2,4-dichloro-N-[4-(5-chloropyridin-3-yl)oxy-3-fluorophenyl]benzenesulfonamide
  参考文献：
  名称：

  Discovery of INT131: A selective PPARγ modulator that enhances insulin sensitivity

  摘要：

  PPAR gamma is a member of the nuclear hormone receptor family and plays a key role in the regulation of glucose homeostasis. This Letter describes the discovery of a novel chemical class of diarylsulfonamide partial agonists that act as selective PPAR gamma modulators (SPPAR gamma Ms) and display a unique pharmacological profile compared to the thiazolidinedione (TZD) class of PPAR gamma full agonists. Herein we report the initial discovery of partial agonist 4 and the structure-activity relationship studies that led to the selection of clinical compound INT131 (3), a potent PPAR gamma partial agonist that displays robust glucose-lowering activity in rodent models of diabetes while exhibiting a reduced side-effects profile compared to marketed TZDs. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.11.058
• 作为产物：
  描述：

  3-fluoro-4-(3-chloro-5-pyridyloxy)nitrobenzene 生成 3-fluoro-4-(3-chloro-5-pyridyloxy)aniline
  参考文献：
  名称：

  Compounds for the modulation of PPARgamma activity

  摘要：

  提供了调节PPAR&ggr;活性的调节剂，可用于制药组合物和治疗类型II糖尿病和肥胖等疾病的方法。

  公开号：

  US20030139390A1

文献信息

• Therapeutic modulation of PPARgamma activity
  申请人：Chen Jin-Long

  公开号：US20050250820A1

  公开（公告）日：2005-11-10

  Modulators of PPARγ activity are used in methods of treating and/or preventing conditions such as osteoporosis, Alzheimer's disease, psoriasis and acne, and cancer.

  PPARγ活性调节剂被用于治疗和/或预防骨质疏松症、阿尔茨海默病、银屑病和痤疮以及癌症等疾病的方法中。
• Compounds for the modulation of PPARgamma activity
  申请人：Tularik Inc.

  公开号：US20030139390A1

  公开（公告）日：2003-07-24

  Modulators of PPAR&ggr; activity are provided which are useful in pharmaceutical compositions and methods for the treatment of conditions such as type II diabetes and obesity.

  提供了调节PPAR&ggr;活性的调节剂，可用于制药组合物和治疗类型II糖尿病和肥胖等疾病的方法。
• [EN] COMPOUNDS FOR THE MODULATION OF PPAR gamma ACTIVITY<br/>[FR] COMPOSES UTILISES POUR LA MODULATION DE L'ACTIVITE DE PPAR gamma
  申请人：TULARIK INC

  公开号：WO2001000579A1

  公开（公告）日：2001-01-04

  Modulators of PPARη activity are provided which are useful in pharmaceutical compositions and methods for the treatment of conditions such as type II diabetes and obesity.

  提供了PPARη活性的调节剂，这些调节剂在制备制药组合物和治疗II型糖尿病和肥胖等疾病的方法中非常有用。
• Compounds for the modulation of PPARy activity
  申请人：Tularik Inc.

  公开号：US20040248882A1

  公开（公告）日：2004-12-09

  Modulators of PPAR&ggr; activity are provided which are useful in pharmaceutical compositions and methods for the treatment of conditions such as type II diabetes and obesity.

  提供了PPAR&ggr;活性调节剂，可用于制备药物组合物和治疗II型糖尿病和肥胖等疾病的方法。
• COMPOUNDS FOR THE MODULATION OF PPARgamma ACTIVITY
  申请人：McGee Lawrence R.

  公开号：US20100113522A1

  公开（公告）日：2010-05-06

  Modulators of PPARγ activity are provided which are useful in pharmaceutical compositions and methods for the treatment of conditions such as type II diabetes and obesity.

  提供了PPARγ活性调节剂，可用于制备药物组合物和治疗2型糖尿病和肥胖等疾病的方法。